Expertise in
7
conditions

Dr. Ashley Shoemaker

Pediatric Endocrinology
Vanderbilt University
2200 Childrens Way, 
Nashville, TN 
Offers Telehealth
Expertise in
7
conditions
Vanderbilt University
2200 Childrens Way, 
Nashville, TN 

Overview

Ashley Shoemaker is a Pediatric Endocrinologist in Nashville, Tennessee. Dr. Shoemaker is highly rated in 7 conditions, according to our data. Her top areas of expertise are Albright's Hereditary Osteodystrophy, Pseudohypoparathyroidism, Prader-Willi Syndrome, and Obesity.

Her clinical research consists of co-authoring 50 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatric Endocrinology

Licenses

Pediatric Endocrinology in TN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 9 Less Insurance Carriers -

Locations

Vanderbilt University
2200 Childrens Way, Nashville, TN 37232
Other Locations
Office
1215 21st Ave S, Nashville, TN 37232

Additional Areas of Focus

Dr. Shoemaker has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Pediatric Growth Hormone Deficiency

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism
Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drug: Theophylline
Study Phase: Phase 2
Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism
Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drug: Theophylline
Study Phase: Phase 2
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2/Phase 3
Vanderbilt Childhood Obesity Registry
Vanderbilt Childhood Obesity Registry
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects With Hypothalamic Obesity
A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects With Hypothalamic Obesity
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Drug: DCCR (diazoxide choline controlled release tablets)
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Enrollment Status: Terminated
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drug: RAD011
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Enrollment Status: Completed
Publish Date: August 18, 2023
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Enrollment Status: Completed
Publish Date: November 15, 2022
Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity
Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity
Enrollment Status: Completed
Publish Date: May 05, 2022
Intervention Type: Drug
Study Phase: Phase 3
Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism
Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism
Enrollment Status: Terminated
Publish Date: May 27, 2021
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: March 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Enrollment Status: Completed
Publish Date: November 13, 2019
View 13 Less Clinical Trials

50 Total Publications

Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Withdrawal Period Study.
Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Withdrawal Period Study.
Journal: The Journal of clinical endocrinology and metabolism
Published: September 15, 2025
Similar Doctors
Expertise in
6
conditions
Dr. Jill Simmons
Pediatric Endocrinology
Expertise in
6
conditions
Dr. Jill Simmons
Pediatric Endocrinology

Vanderbilt Children's Endocrinology

2200 Childrens Way, 
Nashville, TN 
 (0.2 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jill Simmons is a Pediatric Endocrinologist in Nashville, Tennessee. Dr. Simmons is highly rated in 6 conditions, according to our data. Her top areas of expertise are X-Linked Hypophosphatemia, Hypophosphatasia (HPP), Malnutrition, and Type 1 Diabetes (T1D).

Expertise in
2
conditions
Dr. Justin Gregory
Pediatric Endocrinology
Expertise in
2
conditions
Dr. Justin Gregory
Pediatric Endocrinology

Vanderbilt Children's Endocrinology

2200 Childrens Way, 
Nashville, TN 
 (0.2 miles away)
615-555-1212
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Justin Gregory is a Pediatric Endocrinologist in Nashville, Tennessee. Dr. Gregory is highly rated in 2 conditions, according to our data. His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

Expertise in
1
conditions
Dr. Jaclyn Tamaroff
Pediatric Endocrinology
Expertise in
1
conditions
Dr. Jaclyn Tamaroff
Pediatric Endocrinology

Vanderbilt University

3601 21st Ave S, 
Nashville, TN 
 (0.5 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jaclyn Tamaroff is a Pediatric Endocrinologist in Nashville, Tennessee. Dr. Tamaroff is highly rated in 1 condition, according to our data. Her top areas of expertise are Hereditary Ataxia, Brachydactyly, Albright's Hereditary Osteodystrophy, and Pseudohypoparathyroidism.

Frequently Asked Questions about Dr. Ashley Shoemaker

How do I make an appointment with Dr. Ashley Shoemaker?

You can book an appointment with Dr. Ashley Shoemaker by calling their office at 615-322-7427. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ashley Shoemaker a top-rated expert for Albright's Hereditary Osteodystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ashley Shoemaker is classified as an Elite expert for Albright's Hereditary Osteodystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ashley Shoemaker specialize in?

While Dr. Ashley Shoemaker is a Pediatric Endocrinology, they have specific expertise in Albright's Hereditary Osteodystrophy, Pseudohypoparathyroidism, and Prader-Willi Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Endocrinology.

Does Dr. Ashley Shoemaker participate in research or clinical trials?

Yes. Dr. Ashley Shoemaker has published 50 articles and abstracts on conditions like Albright's Hereditary Osteodystrophy. You can view a list of Dr. Ashley Shoemaker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ashley Shoemaker accept my insurance?

Dr. Ashley Shoemaker accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 615-322-7427 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shoemaker's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile